Basic Information
| LncRNA/CircRNA Name | SRRM2-AS |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | Western blot, Microarray |
| Sample | NPC tissues |
| Expression Pattern | up-regulated |
| Function Description | SRRM2-AS was highly expressed and MYLK was poorly expressed in NPC tissues. silencing of SRRM2-AS protected against angiogenesis of NPC cells by upregulating MYLK and activating the cGMP-PKG signaling pathway, which provides a new target for NPC treatment. |
| Pubmed ID | 31742692 |
| Year | 2019 |
| Title | Silencing of long noncoding RNA SRRM2-AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK-mediated cGMP-PKG signaling pathway |
External Links
| Links for SRRM2-AS | GenBank HGNC NONCODE |
| Links for nasopharyngeal cancer | OMIM COSMIC |